...
首页> 外文期刊>Bone marrow transplantation >Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children.
【24h】

Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children.

机译:异基因HCT后自体细胞数量增多的儿童立即开始免疫治疗可诱导完全的供体型嵌合体:14位儿童的报告。

获取原文
获取原文并翻译 | 示例

摘要

Immunotherapy consisting of withdrawal of immunosuppression and/or donor lymphocyte infusions was initiated in 14 children (10 acute lymphoblastic leukemia, three acute myeloblastic leukemia and one myelodysplastic syndrome) with an increasing amount of autologous DNA (increasing mixed chimerism, inMC) detected after allogeneic hematopoietic cell transplantation (HCT). Two children were in relapse when inMC was detected, 12 remained in CR. Children with overt relapse at the time of cessation of cyclosporine A (CsA) received "debulking" chemotherapy. One of them developed acute grade III graft-versus-host disease, converted to complete donor chimerism (CC) and achieved remission. Another patient did not respond and died due to disease progression. Among 12 children treated in remission, 11 responded with conversion to CC, seven after CsA withdrawal and four after DLI. One patient did not respond, rejected the graft and died due to pulmonary aspergillosis. In one patient, the response was transient, inMCreappeared and frank relapse occurred. One patient developed isolated CNS relapse despite conversion to CC, but achieved CR after conventional treatment. One child died in CC due to infection. No graft-versus-host disease (GvHD)-related death occurred. A total of 10 patients are alive in remission with median follow-up of 338 days. Our results support the hypothesis that chimerism-guided immunotherapy after alloHCT may prevent progression to hematological relapse.
机译:在同种异体造血后发现14例儿童(10例急性淋巴细胞性白血病,3例急性粒细胞性白血病和1例骨髓增生异常综合征)中开始进行免疫治疗,包括撤回免疫抑制和/或输注淋巴细胞,其中自体DNA量增加(混合嵌合体,inMC增多)。细胞移植(HCT)。检测到inMC时有2名儿童复发,CR中还有12名儿童。停止使用环孢素A(CsA)时明显复发的儿童接受了“减量”化疗。其中一名发展为急性III级移植物抗宿主病,转变为完全供体嵌合症(CC),并获得缓解。另一例患者没有反应,并因疾病进展而死亡。在12例缓解的儿童中,有11例转换为CC,CsA退出后7例,DLI以后4例。一名患者无反应,拒绝移植并死于肺曲霉病。在一名患者中,反应是暂时的,MC再次出现,并出现坦率的复发。尽管转化为CC,一名患者仍出现孤立的CNS复发,但在常规治疗后达到CR。一名儿童因感染在CC中死亡。没有发生移植物抗宿主病(GvHD)相关的死亡。共有10例患者存活,其中位随访时间为338天。我们的研究结果支持以下假设:alloHCT后嵌合体指导的免疫治疗可能会阻止血液学复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号